Search

Your search keyword '"Bar, Merav"' showing total 303 results
Start Over Author "Bar, Merav"
303 results on '"Bar, Merav"'

2. HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation

Author

Krakow, Elizabeth F., Brault, Michelle, Summers, Corinne, Cunningham, Tanya M., Biernacki, Melinda A., Black, R. Graeme, Woodward, Kyle B., Vartanian, Nicole, Kanaan, Sami B., Yeh, Albert C., Dossa, Robson G., Bar, Merav, Cassaday, Ryan D., Dahlberg, Ann, Till, Brian G., Denker, Andrew E., Yeung, Cecilia C. S., Gooley, Ted A., Maloney, David G., Riddell, Stanley R., Greenberg, Philip D., Chapuis, Aude G., Newell, Evan W., Furlan, Scott N., and Bleakley, Marie

Published
2024
Full Text
View/download PDF

3. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)

Author

Kansagra, Ankit J, Frey, Noelle V, Bar, Merav, Laetsch, Theodore W, Carpenter, Paul A, Savani, Bipin N, Heslop, Helen E, Bollard, Catherine M, Komanduri, Krishna V, Gastineau, Dennis A, Chabannon, Christian, Perales, Miguel A, Hudecek, Michael, Aljurf, Mahmoud, Andritsos, Leslie, Barrett, John A, Bachanova, Veronika, Bonini, Chiara, Ghobadi, Armin, Gill, Saar I, Hill, Joshua A, Kenderian, Saad, Kebriaei, Partow, Nagler, Arnon, Maloney, David, Liu, Hien D, Shah, Nirali N, Kharfan-Dabaja, Mohamed A, Shpall, Elizabeth J, Mufti, Ghulam J, Johnston, Laura, Jacoby, Elad, Bazarbachi, Ali, DiPersio, John F, Pavletic, Steven Z, Porter, David L, Grupp, Stephan A, Sadelain, Michel, Litzow, Mark R, Mohty, Mohamad, and Hashmi, Shahrukh K

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Pediatric, Childhood Leukemia, Immunization, Genetics, Transplantation, Biotechnology, Gene Therapy, Pediatric Cancer, Pediatric Research Initiative, Hematology, Orphan Drug, Rare Diseases, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Good Health and Well Being, Clinical Sciences, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Published
2019

4. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy

Author

Kansagra, Ankit J, Frey, Noelle V, Bar, Merav, Laetsch, Theodore W, Carpenter, Paul A, Savani, Bipin N, Heslop, Helen E, Bollard, Catherine M, Komanduri, Krishna V, Gastineau, Dennis A, Chabannon, Christian, Perales, Miguel A, Hudecek, Michael, Aljurf, Mahmoud, Andritsos, Leslie, Barrett, John A, Bachanova, Veronika, Bonini, Chiara, Ghobadi, Armin, Gill, Saar I, Hill, Joshua, Kenderian, Saad, Kebriaei, Partow, Nagler, Arnon, Maloney, David, Liu, Hien D, Shah, Nirali N, Kharfan-Dabaja, Mohamed A, Shpall, Elizabeth J, Mufti, Ghulam J, Johnston, Laura, Jacoby, Elad, Bazarbachi, Ali, DiPersio, John F, Pavletic, Steven Z, Porter, David L, Grupp, Stephan A, Sadelain, Michel, Litzow, Mark R, Mohty, Mohamad, and Hashmi, Shahrukh K

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Transplantation, Childhood Leukemia, Pediatric Cancer, Pediatric, Biotechnology, Orphan Drug, Genetics, Pediatric Research Initiative, Cancer, Rare Diseases, Gene Therapy, Immunization, Hematology, Development of treatments and therapeutic interventions, 5.2 Cellular and gene therapies, Good Health and Well Being, Antigens, CD19, Child, Critical Pathways, Drug Approval, Expert Testimony, Humans, Immunotherapy, Adoptive, Practice Patterns, Physicians', Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Receptors, Antigen, T-Cell, Societies, Medical, United States, Young Adult, Chimeric antigen receptor, Leukemia, T cell, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

On August 30, 2017 the US Food and Drug Administration approved tisagenlecleucel (Kymriah; Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present, ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring, and disease assessments. To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.

Published
2019

6. Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T‐Cell Engager, Using Population Pharmacokinetics and Exposure–Response Analysis.

Author

Kiesel, Brian, Osawa, Mayu, Masilamani, Madhan, Bar, Merav, Hsu, Kevin, Godwin, Colin, Burgess, Michael, Lamba, Manisha, and Gaudy, Allison

Subjects
MULTIPLE myeloma, CLINICAL pharmacology, ANTINEOPLASTIC agents, PHARMACOKINETICS, CRITICAL analysis
Abstract

Alnuctamab, a B‐cell maturation antigen (BCMA)‐targeting T‐cell engager, has demonstrated encouraging antitumor activity in the phase I study CC‐93269‐MM‐001 treating patients with relapsed or refractory multiple myeloma. Identification of a recommended Phase III dose (RP3D) was a key objective, as such population pharmacokinetic (PopPK) and exposure–response analysis was critical. Intravenous (IV) alnuctamab was administered in fixed doses (0.15–10 mg) or in step‐up doses to a maximum 10‐mg target dose. Subcutaneous (SC) step‐up doses of 3 and 6 mg were followed by a target dose range of 10–60 mg. Concentration data from IV and SC alnuctamab administration was pooled and was well described by a two‐compartment PopPK model with first‐order absorption and elimination. Covariate analysis determined that the inclusion of baseline soluble BCMA (sBCMA) on clearance significantly improved model fitting. Individual exposure parameters were estimated from the final model to characterize exposure–response relationships. Switching from IV to SC administration improved the safety profile of alnuctamab by limiting the frequency of grade ≥2 CRS events. A significant exposure–CRS relationship was observed after the first SC dose, but not subsequent dose administrations. Exposure–safety analysis did not find a statistically significant relationship between increasing exposure and the probability of key safety events of interest. Logistic regression analysis for patients administered SC alnuctamab identified that increased exposure significantly increased the probability of response, although the additional benefit was minimal at exposures above 30 mg target dose. Considering the totality of exposure–response data, the clinical pharmacology assessment supported a SC RP3D of 3/6/30 mg. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Aljurf, Mahmoud, Nishihori, Taiga, Marsh, Rebecca, Burroughs, Lauri M., Majhail, Navneet, Al-Homsi, A. Samer, Al-Kadhimi, Zaid S., Bar, Merav, Bertaina, Alice, Boelens, Jaap J., Champlin, Richard, Chaudhury, Sonali, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, El-Jawahri, Areej, Fanning, Suzanne, Fraint, Ellen, Gergis, Usama, Giralt, Sergio, Hamilton, Betty K., Hashmi, Shahrukh K., Horn, Biljana, Inamoto, Yoshihiro, Jacobsohn, David A, Jain, Tania, Johnston, Laura, Kanate, Abraham S., Kansagra, Ankit, Kassim, Adetola, Kean, Leslie S., Kitko, Carrie L., Knight-Perry, Jessica, Kurtzberg, Joanne, Liu, Hien, MacMillan, Margaret L., Mahmoudjafari, Zahra, Mielcarek, Marco, Mohty, Mohamad, Nagler, Arnon, Nemecek, Eneida, Olson, Timothy S., Oran, Betul, Perales, Miguel-Angel, Prockop, Susan E., Pulsipher, Michael A., Pusic, Iskra, Riches, Marcie L., Rodriguez, Cesar, Romee, Rizwan, Rondon, Gabriela, Saad, Ayman, Shah, Nina, Shaw, Peter J., Shenoy, Shalini, Sierra, Jorge, Talano, Julie, Verneris, Michael R., Veys, Paul, Wagner, John E., Savani, Bipin N., Hamadani, Mehdi, and Carpenter, Paul A.

Published
2021
Full Text
View/download PDF

8. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies

Author

Gauthier, Jordan, Bezerra, Evandro D., Hirayama, Alexandre V., Fiorenza, Salvatore, Sheih, Alyssa, Chou, Cassie K., Kimble, Erik L., Pender, Barbara S., Hawkins, Reed M., Vakil, Aesha, Phi, Tinh-Doan, Steinmetz, Rachel N., Jamieson, Abby W., Bar, Merav, Cassaday, Ryan D., Chapuis, Aude G., Cowan, Andrew J., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2021
Full Text
View/download PDF

10. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Author

Bar, Merav, Ott, Susan M., Lewiecki, E. Michael, Sarafoglou, Kyriakie, Wu, Joy Y., Thompson, Matthew J., Vaux, Jonathan J., Dean, David R., Saag, Kenneth G., Hashmi, Shahrukh K., Inamoto, Yoshihiro, Dholaria, Bhagirathbhai R., Kharfan-Dabaja, Mohamed A., Nagler, Arnon, Rodriguez, Cesar, Hamilton, Betty K., Shah, Nina, Flowers, Mary E.D., Savani, Bipin N., and Carpenter, Paul A.

Published
2020
Full Text
View/download PDF

14. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Author

Jain, Tania, Bar, Merav, Kansagra, Ankit J., Chong, Elise A., Hashmi, Shahrukh K., Neelapu, Sattva S., Byrne, Michael, Jacoby, Elad, Lazaryan, Aleksandr, Jacobson, Caron A., Ansell, Stephen M., Awan, Farrukh T., Burns, Linda, Bachanova, Veronika, Bollard, Catherine M., Carpenter, Paul A., DiPersio, John F., Hamadani, Mehdi, Heslop, Helen E., Hill, Joshua A., Komanduri, Krishna V., Kovitz, Craig A., Lazarus, Hillard M., Serrette, Justin M., Mohty, Mohamad, Miklos, David, Nagler, Arnon, Pavletic, Steven Z., Savani, Bipin N., Schuster, Stephen J., Kharfan-Dabaja, Mohamed A., Perales, Miguel-Angel, and Lin, Yi

Published
2019
Full Text
View/download PDF

16. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling

Author

Bader, Peter, Salzmann-Manrique, Emilia, Balduzzi, Adriana, Dalle, Jean-Hugues, Woolfrey, Ann E., Bar, Merav, Verneris, Michael R., Borowitz, Michael J., Shah, Nirali N., Gossai, Nathan, Shaw, Peter J., Chen, Allen R., Schultz, Kirk R., Kreyenberg, Hermann, Di Maio, Lucia, Cazzaniga, Gianni, Eckert, Cornelia, van der Velden, Vincent H.J., Sutton, Rosemary, Lankester, Arjan, Peters, Christina, Klingebiel, Thomas E., Willasch, Andre M., Grupp, Stephan A., and Pulsipher, Michael A.

Published
2019
Full Text
View/download PDF

18. Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial

Author

Abdallah, Al-Ola, primary, Lesokhin, Alexander, additional, Wrobel, Tomasz, additional, Jamroziak, Krzysztof, additional, Dytfeld, Dominik, additional, Touzeau, Cyrille, additional, Suvannasankha, Attaya, additional, Leleu, Xavier, additional, Silbermann, Rebecca, additional, Khan, Abdullah M., additional, Kumar, Shaji, additional, Gertz, Morie, additional, Laubach, Jacob P., additional, Jou, Ying-Ming, additional, Bar, Merav, additional, Das, Prianka, additional, Wang, Yu, additional, Demers, Korey, additional, Stong, Nicholas, additional, Perumal, Deepak, additional, La Motte-Mohs, Ross, additional, MacLachlan, Kylee, additional, and Dimopoulos, Meletios-Athanasios, additional

Published
2023
Full Text
View/download PDF

21. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Author

Chapuis, Aude G., Egan, Daniel N., Bar, Merav, Schmitt, Thomas M., McAfee, Megan S., Paulson, Kelly G., Voillet, Valentin, Gottardo, Raphael, Ragnarsson, Gunnar B., Bleakley, Marie, Yeung, Cecilia C., Muhlhauser, Petri, Nguyen, Hieu N., Kropp, Lara A., Castelli, Luca, Wagener, Felecia, Hunter, Daniel, Lindberg, Marcus, Cohen, Kristen, Seese, Aaron, McElrath, M. Juliana, Duerkopp, Natalie, Gooley, Ted A., and Greenberg, Philip D.

Published
2019
Full Text
View/download PDF

23. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Author

Mathew, Nimitha R, Baumgartner, Francis, Braun, Lukas, O'Sullivan, David, Thomas, Simone, Waterhouse, Miguel, Müller, Tony A, Hanke, Kathrin, Taromi, Sanaz, Apostolova, Petya, Illert, Anna L, Melchinger, Wolfgang, Duquesne, Sandra, Schmitt-Graeff, Annette, Osswald, Lena, Yan, Kai-Li, Weber, Arnim, Tugues, Sonia, Spath, Sabine, Pfeifer, Dietmar, Follo, Marie, Claus, Rainer, Lübbert, Michael, Rummelt, Christoph, Bertz, Hartmut, Wäsch, Ralph, Haag, Johanna, Schmidts, Andrea, Schultheiss, Michael, Bettinger, Dominik, Thimme, Robert, Ullrich, Evelyn, Tanriver, Yakup, Vuong, Giang Lam, Arnold, Renate, Hemmati, Philipp, Wolf, Dominik, Ditschkowski, Markus, Jilg, Cordula, Wilhelm, Konrad, Leiber, Christian, Gerull, Sabine, Halter, Jörg, Lengerke, Claudia, Pabst, Thomas, Schroeder, Thomas, Kobbe, Guido, Rösler, Wolf, Doostkam, Soroush, Meckel, Stephan, Stabla, Kathleen, Metzelder, Stephan K, Halbach, Sebastian, Brummer, Tilman, Hu, Zehan, Dengjel, Joern, Hackanson, Björn, Schmid, Christoph, Holtick, Udo, Scheid, Christof, Spyridonidis, Alexandros, Stölzel, Friedrich, Ordemann, Rainer, Müller, Lutz P, Sicre-de-Fontbrune, Flore, Ihorst, Gabriele, Kuball, Jürgen, Ehlert, Jan E, Feger, Daniel, Wagner, Eva-Maria, Cahn, Jean-Yves, Schnell, Jacqueline, Kuchenbauer, Florian, Bunjes, Donald, Chakraverty, Ronjon, Richardson, Simon, Gill, Saar, Kröger, Nicolaus, Ayuk, Francis, Vago, Luca, Ciceri, Fabio, Müller, Antonia M, Kondo, Takeshi, Teshima, Takanori, Klaeger, Susan, Kuster, Bernhard, Weisdorf, Daniel, van der Velden, Walter, Dörfel, Daniela, Bethge, Wolfgang, Hilgendorf, Inken, Hochhaus, Andreas, Andrieux, Geoffroy, Börries, Melanie, Busch, Hauke, Magenau, John, Reddy, Pavan, Labopin, Myriam, Antin, Joseph H, Henden, Andrea S, Hill, Geoffrey R, Kennedy, Glen A, Bar, Merav, Sarma, Anita, McLornan, Donal, Mufti, Ghulam, Oran, Betul, Rezvani, Katayoun, Shah, Omid, Negrin, Robert S, Nagler, Arnon, Prinz, Marco, Burchert, Andreas, Neubauer, Andreas, Beelen, Dietrich, Mackensen, Andreas, von Bubnoff, Nikolas, Herr, Wolfgang, Becher, Burkhard, Socié, Gerard, Caligiuri, Michael A, Ruggiero, Eliana, Bonini, Chiara, Häcker, Georg, Duyster, Justus, Finke, Jürgen, Pearce, Erika, Blazar, Bruce R, and Zeiser, Robert

Subjects
Interleukin-15 -- Health aspects, Gene mutation -- Health aspects, Sorafenib -- Patient outcomes, Gene expression -- Health aspects, Acute myelocytic leukemia -- Genetic aspects -- Development and progression -- Drug therapy, Biological sciences, Health
Abstract

Individuals with acute myeloid leukemia (AML) harboring an internal tandem duplication (ITD) in the gene encoding Fms-related tyrosine kinase 3 (FLT3) who relapse after allogeneic hematopoietic cell transplantation (allo-HCT) have a 1-year survival rate below 20%. We observed that sorafenib, a multitargeted tyrosine kinase inhibitor, increased IL-15 production by FLT3-ITD[sup.+] leukemia cells. This synergized with the allogeneic CD8[sup.+] T cell response, leading to long-term survival in six mouse models of FLT3-ITD[sup.+] AML. Sorafenib-related IL-15 production caused an increase in CD8[sup.+]CD107a[sup.+]IFN-[gamma][sup.+] T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which eradicated leukemia in secondary recipients. Mechanistically, sorafenib reduced expression of the transcription factor ATF4, thereby blocking negative regulation of interferon regulatory factor 7 (IRF7) activation, which enhanced IL-15 transcription. Both IRF7 knockdown and ATF4 overexpression in leukemia cells antagonized sorafenib-induced IL-15 production in vitro. Human FLT3-ITD[sup.+] AML cells obtained from sorafenib responders following sorafenib therapy showed increased levels of IL-15, phosphorylated IRF7, and a transcriptionally active IRF7 chromatin state. The mitochondrial spare respiratory capacity and glycolytic capacity of CD8[sup.+] T cells increased upon sorafenib treatment in sorafenib responders but not in nonresponders. Our findings indicate that the synergism of T cells and sorafenib is mediated via reduced ATF4 expression, causing activation of the IRF7-IL-15 axis in leukemia cells and thereby leading to metabolic reprogramming of leukemia-reactive T cells in humans. Therefore, sorafenib treatment has the potential to contribute to an immune-mediated cure of FLT3-ITD-mutant AML relapse, an otherwise fatal complication after allo-HCT., Author(s): Nimitha R Mathew [1, 2]; Francis Baumgartner [1]; Lukas Braun [1]; David O'Sullivan [3]; Simone Thomas [4]; Miguel Waterhouse [1]; Tony A Müller [1]; Kathrin Hanke [1, 2]; Sanaz [...]

Published
2018
Full Text
View/download PDF

24. Supplementary Table 6 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 3 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 1 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 5 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 7 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figures 1-12 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Methods, Figures 1-11, Table Legends 1-7 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

31. Data from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 4 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 2 from HIF Induces Human Embryonic Stem Cell Markers in Cancer Cells

Author

Mathieu, Julie, primary, Zhang, Zhan, primary, Zhou, Wenyu, primary, Wang, Amy J., primary, Heddleston, John M., primary, Pinna, Claudia M.A., primary, Hubaud, Alexis, primary, Stadler, Bradford, primary, Choi, Michael, primary, Bar, Merav, primary, Tewari, Muneesh, primary, Liu, Alvin, primary, Vessella, Robert, primary, Rostomily, Robert, primary, Born, Donald, primary, Horwitz, Marshall, primary, Ware, Carol, primary, Blau, C. Anthony, primary, Cleary, Michele A., primary, Rich, Jeremy N., primary, and Ruohola-Baker, Hannele, primary

Published
2023
Full Text
View/download PDF

36. Treosulfan, Fludarabine, and 2-Gy Total Body Irradiation Followed by Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Author

Gyurkocza, Boglarka, Gutman, Jonathan, Nemecek, Eneida R., Bar, Merav, Milano, Filippo, Ramakrishnan, Aravind, Scott, Bart, Fang, Min, Wood, Brent, Pagel, John M., Baumgart, Joachim, Delaney, Colleen, Maziarz, Richard T., Sandmaier, Brenda M., Estey, Elihu H., Appelbaum, Frederick R., Storer, Barry E., and Deeg, Hans Joachim

Published
2014
Full Text
View/download PDF

38. Targeting an alternate Wilms’ tumor antigen 1 peptide bypasses immunoproteasome dependency

Author

Lahman, Miranda C., primary, Schmitt, Thomas M., additional, Paulson, Kelly G., additional, Vigneron, Nathalie, additional, Buenrostro, Denise, additional, Wagener, Felecia D., additional, Voillet, Valentin, additional, Martin, Lauren, additional, Gottardo, Raphael, additional, Bielas, Jason, additional, McElrath, Julie M., additional, Stirewalt, Derek L., additional, Pogosova-Agadjanyan, Era L., additional, Yeung, Cecilia C., additional, Pierce, Robert H., additional, Egan, Daniel N., additional, Bar, Merav, additional, Hendrie, Paul C., additional, Kinsella, Sinéad, additional, Vakil, Aesha, additional, Butler, Jonah, additional, Chaffee, Mary, additional, Linton, Jonathan, additional, McAfee, Megan S., additional, Hunter, Daniel S., additional, Bleakley, Marie, additional, Rongvaux, Anthony, additional, Van den Eynde, Benoit J., additional, Chapuis, Aude G., additional, and Greenberg, Philip D., additional

Published
2022
Full Text
View/download PDF

39. MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Author

Brooks, Erin, primary, Spahn, Ashley, additional, Waldvogel, Stephanie, additional, Howard, Alan, additional, Bar, Merav, additional, Bratrude, Brandi, additional, Chhabra, Saurabh, additional, Clark, William, additional, Das, Suman Ranjan, additional, Horowitz, Mary M., additional, Jenq, Robert R., additional, Jones, Richard J., additional, Levine, John E., additional, Logan, Brent R., additional, Murthy, Hemant S., additional, Rashidi, Armin, additional, Riches, Marcie L., additional, Riwes, Mary Mansour, additional, Sandhu, Karamjeet S., additional, Sung, Anthony D., additional, Al Malki, Monzr M., additional, Runaas, Lyndsey, additional, Elmariah, Hany, additional, Rezvani, Andrew R., additional, Gooptu, Mahasweta, additional, Bolaños-Meade, Javier, additional, Holtan, Shernan G, additional, Saber, Wael, additional, Hamadani, Mehdi, additional, Kean, Leslie S, additional, Perales, Miguel-Angel, additional, and Bhatt, Ami S., additional

Published
2021
Full Text
View/download PDF

42. Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study

Author

Kean, Leslie, Siegel, Steven J, Schmalz, Joseph T, Bien, Stephanie A, Scheffey, Danielle, Sanders, Catherine, Robins, Harlan, Applegate, Kristy, Bar, Merav, Chhabra, Saurabh, Choi, Sung W., Clark, William, Das, Suman r, Jenq, Robert R., Jones, Richard J., Levine, John, Logan, Brent R., Murthy, Hemant S., Rashidi, Armin, Riches, Marcie L., Saber, Wael, Sandhu, Karamjeet S., Sung, Anthony D., Larkin, Karilyn, Al Malki, Monzr M., Gooptu, Mahasweta, Elmariah, Hany, Alousi, Amin, Runaas, Lyndsey, Shaffer, Brian C., Rezvani, Andrew R., El Jurdi, Najla, Loren, Alison, Horowitz, Mary M., Bolanos-Meade, Javier, Holtan, Shernan G., Bhatt, Ami S., Perales, Miguel-Angel, and DeWolf, Susan

Published
2023
Full Text
View/download PDF

43. Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies

Author

Walti, Carla S., primary, Krantz, Elizabeth M., additional, Maalouf, Joyce, additional, Boonyaratanakornkit, Jim, additional, Keane-Candib, Jacob, additional, Joncas-Schronce, Laurel, additional, Stevens-Ayers, Terry, additional, Dasgupta, Sayan, additional, Taylor, Justin J., additional, Hirayama, Alexandre V., additional, Bar, Merav, additional, Gardner, Rebecca A., additional, Cowan, Andrew J., additional, Green, Damian J., additional, Boeckh, Michael J., additional, Maloney, David G., additional, Turtle, Cameron J., additional, and Hill, Joshua A., additional

Published
2021
Full Text
View/download PDF

45. Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Author

Shadman, Mazyar, primary, Yeung, Cecilia, additional, Redman, Mary W, additional, Lee, Sang Yun, additional, Lee, Dong Hoon, additional, Ramachandran, Ajeetha, additional, Ra, Susan, additional, Marzbani, Edmond A, additional, Graf, Solomon A., additional, Warren, Edus H., additional, Gopal, Ajay K., additional, Chapuis, Aude G., additional, Bar, Merav, additional, Green, Damian J., additional, Gauthier, Jordan, additional, Cassaday, Ryan D., additional, Kiem, Hans-Peter, additional, Turtle, Cameron J., additional, Maloney, David G., additional, and Till, Brian G., additional

Published
2020
Full Text
View/download PDF

46. Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress

Author

Krakow, Elizabeth F, primary, Summers, Corinne, additional, Dahlberg, Ann, additional, Bar, Merav, additional, Biernacki, Melinda Ann, additional, Cunningham, Tanya, additional, Vartanian, Nicole, additional, Hickner, Megan, additional, Chaney, Colette, additional, Habtetsion, Tsadik, additional, Woodward, Kyle, additional, Dossa, Robson, additional, Brault, Michelle, additional, and Bleakley, Marie, additional

Published
2020
Full Text
View/download PDF

47. Pre-Transplant Gene Expression May Predict Risk of Graft Versus Host Disease

Author

Bar, Merav, primary, Rinchai, Darawan, additional, Toufiq, Mohammed, additional, Elanbari, Mohammed, additional, Kizhakayil, Dhanya, additional, Manjunath, Harshitha Shobha, additional, Mathew, Rebecca, additional, Cavattoni, Irene M, additional, Forer, Sabine, additional, Brown, Clarisa, additional, Miles, Nancy, additional, Tomei, Sara, additional, Cugno, Chiara, additional, Chaussabel, Damien, additional, and Deola, Sara, additional

Published
2020
Full Text
View/download PDF

49. 196. Antibodies to Vaccine-preventable Infections After CAR-T Cell Immunotherapy for B Cell Malignancies

Author

Walti, Carla S, primary, Maalouf, Joyce, additional, Boonyaratanakornkit, Jim, additional, Keane-Candib, Jacob, additional, Taylor, Justin J, additional, Hirayama, Alexandre V, additional, Bar, Merav, additional, Gardner, Rebecca A, additional, Green, Damian J, additional, Boeckh, Michael, additional, Maloney, David G, additional, Krantz, Elizabeth M, additional, Turtle, Cameron J, additional, and Hill, Joshua A, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results